[HTML][HTML] Regulation of IL-10 and IL-12 production and function in macrophages and dendritic cells
Abstract Interleukin-10 and Interleukin-12 are produced primarily by pathogen-activated
antigen-presenting cells, particularly macrophages and dendritic cells. IL-10 and IL-12 play …
antigen-presenting cells, particularly macrophages and dendritic cells. IL-10 and IL-12 play …
Antibody-cytokine fusion proteins for improving efficacy and safety of cancer therapy
Z Valedkarimi, H Nasiri, L Aghebati-Maleki… - Biomedicine & …, 2017 - Elsevier
Cytokines are key players in the regulation of immune responses both in physiological and
pathological states. A number of cytokines have been evaluated in clinical trials and shown …
pathological states. A number of cytokines have been evaluated in clinical trials and shown …
Aloe-emodin exerts a potent anticancer and immunomodulatory activity on BRAF-mutated human melanoma cells
C Tabolacci, M Cordella, L Turcano, S Rossi… - European journal of …, 2015 - Elsevier
Aim of this study was to extend the knowledge on the antineoplastic effect of aloe-emodin
(AE), a natural hydroxyanthraquinone compound, both in metastatic human melanoma cell …
(AE), a natural hydroxyanthraquinone compound, both in metastatic human melanoma cell …
Adoptive T Cell Therapy with IL-12–Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance …
CG Tucker, JS Mitchell, T Martinov… - The Journal of …, 2020 - journals.aai.org
Optimal ex vivo expansion protocols of tumor-specific T cells followed by adoptive cell
therapy must yield T cells able to home to tumors and effectively kill them. Our previous …
therapy must yield T cells able to home to tumors and effectively kill them. Our previous …
Granulocyte-macrophage colony-stimulating factor increases tumor growth and angiogenesis directly by promoting endothelial cell function and indirectly by …
Q Zheng, X Li, X Cheng, T Cui, Y Zhuo, W Ma… - Tumor …, 2017 - journals.sagepub.com
Granulocyte-macrophage colony-stimulating factor has been widely used as an adjuvant
therapy for cancer patients exhibiting myelosuppression induced by chemotherapy or …
therapy for cancer patients exhibiting myelosuppression induced by chemotherapy or …
Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma
AA Tarhini, I Joshi, F Garner - Immunotherapy, 2021 - Taylor & Francis
The use of immune checkpoint inhibitors in patients with metastatic melanoma generates
clinical benefit, including improved survival. Yet disease resistance and immune-related …
clinical benefit, including improved survival. Yet disease resistance and immune-related …
Silencing of Foxp3 enhances the antitumor efficacy of GM-CSF genetically modified tumor cell vaccine against B16 melanoma
The antitumor response after therapeutic vaccination has a limited effect and seems to be
related to the presence of T regulatory cells (Treg), which express the immunoregulatory …
related to the presence of T regulatory cells (Treg), which express the immunoregulatory …
[PDF][PDF] Efficacy of hydrodynamic interleukin 10 gene transfer in human liver segments with interest in transplantation
L Sendra Gisbert, A Miguel Matas… - Liver …, 2017 - Wiley Online Library
Different diseases lead, during their advanced stages, to chronic or acute liver failure, whose
unique treatment consists in organ transplantation. The success of intervention is limited by …
unique treatment consists in organ transplantation. The success of intervention is limited by …
Recombinant human granulocyte macrophage colony stimulating factor (hGM-CSF): Possibility of nanoparticle-mediated delivery in cancer immunotherapy
Most of the cancer treatment strategies from chemotherapy to radiotherapy render cancer
cells apoptotic and these apoptotic cancer cells accumulate at the tumor sites. The …
cells apoptotic and these apoptotic cancer cells accumulate at the tumor sites. The …
Enhanced anti-tumor immunity against breast cancer induced by whole tumor cell vaccines genetically modified expressing α-Gal epitopes
D Xue, Y Liang, S Duan, J He, J Su… - Oncology …, 2016 - spandidos-publications.com
Whole tumor cell vaccines have shown much promise, but demonstrated poor efficiency in
phase III trials. In this study, we modified MDA-MB‑231 tumor cells (MDA-MB‑231Gal+) to …
phase III trials. In this study, we modified MDA-MB‑231 tumor cells (MDA-MB‑231Gal+) to …